PT2326665E - Proteínas de fusão não citotóxicas compreendendo muteínas de egf - Google Patents

Proteínas de fusão não citotóxicas compreendendo muteínas de egf

Info

Publication number
PT2326665E
PT2326665E PT97855027T PT09785502T PT2326665E PT 2326665 E PT2326665 E PT 2326665E PT 97855027 T PT97855027 T PT 97855027T PT 09785502 T PT09785502 T PT 09785502T PT 2326665 E PT2326665 E PT 2326665E
Authority
PT
Portugal
Prior art keywords
fusion proteins
egf
cancer
suppressing
cytotoxic fusion
Prior art date
Application number
PT97855027T
Other languages
English (en)
Inventor
John Chaddock
Patrick Stancombe
Aimee Cossins
Ian Birch-Machin
Matthew Beard
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of PT2326665E publication Critical patent/PT2326665E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT97855027T 2008-08-21 2009-08-19 Proteínas de fusão não citotóxicas compreendendo muteínas de egf PT2326665E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0815264.7A GB0815264D0 (en) 2008-08-21 2008-08-21 Non-cytotoxic proteins

Publications (1)

Publication Number Publication Date
PT2326665E true PT2326665E (pt) 2013-12-23

Family

ID=39812369

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97855027T PT2326665E (pt) 2008-08-21 2009-08-19 Proteínas de fusão não citotóxicas compreendendo muteínas de egf

Country Status (9)

Country Link
US (1) US8614069B2 (pt)
EP (1) EP2326665B1 (pt)
JP (1) JP5658152B2 (pt)
DK (1) DK2326665T3 (pt)
ES (1) ES2436816T3 (pt)
GB (1) GB0815264D0 (pt)
PL (1) PL2326665T3 (pt)
PT (1) PT2326665E (pt)
WO (1) WO2010020811A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
EP2310029B1 (en) 2008-06-12 2019-04-03 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of cancer
AU2011323832B2 (en) * 2010-10-25 2016-06-02 Niiki Pharma Inc. Method of treating neuroendocrine tumors
KR101519118B1 (ko) * 2013-07-23 2015-05-12 (주)피앤피바이오팜 고안정성 상피세포 성장인자 변이체
IL254577B2 (en) 2015-03-31 2023-11-01 Vhsquared Ltd polypeptides
WO2016156466A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
AU2019211190B2 (en) 2018-01-29 2021-07-08 Ipsen Biopharm Limited Non-neuronal SNARE-cleaving botulinum neurotoxins
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
JP2022530343A (ja) * 2019-04-23 2022-06-29 オーロラ オンコロジー 拡張性組織の治療のための組成物および方法
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
WO2003066677A1 (fr) * 2002-02-05 2003-08-14 Japan Science And Technology Agency Complexe egf/egfr
US8247531B2 (en) * 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
GB0725321D0 (en) * 2007-12-31 2008-02-06 Syntaxin Ltd Delivery vehicles

Also Published As

Publication number Publication date
GB0815264D0 (en) 2008-09-24
WO2010020811A1 (en) 2010-02-25
EP2326665B1 (en) 2013-10-09
DK2326665T3 (da) 2013-11-25
JP5658152B2 (ja) 2015-01-21
JP2012500018A (ja) 2012-01-05
ES2436816T3 (es) 2014-01-07
US20110177056A1 (en) 2011-07-21
PL2326665T3 (pl) 2014-03-31
EP2326665A1 (en) 2011-06-01
US8614069B2 (en) 2013-12-24

Similar Documents

Publication Publication Date Title
PT2326665E (pt) Proteínas de fusão não citotóxicas compreendendo muteínas de egf
IL243812A0 (en) Compounds of diarylhydantoin
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
MX2019011494A (es) Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
CL2008002397A1 (es) Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna.
NZ713641A (en) Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
SG170809A1 (en) Diarylthiohydantoin compounds
EP2283860A3 (en) Use for interleukin-33 (il-33) and the il-33 receptor complex
NZ606195A (en) Methods and compositions for liver cancer therapy
MX336830B (es) Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2007056049A3 (en) Molecular profiling of cancer
MY159837A (en) Therapeutic dll4 binding proteins
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
WO2007101235A3 (en) Improved antitumoral treatments
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF EGFR MUTATIONS IN CASES OF CANCER
ES2422429T3 (es) Diagnóstico del cáncer de próstata
EP2001487A4 (en) FLUORINATED CARBOHYDRATES AND THEIR USE IN THE VISUALIZATION OF TUMORS, TISSUE TREATMENT AND CANCER CHEMOTHERAPY
TN2011000292A1 (en) Amino pyrazole compound
MX2015015115A (es) Metodos de tratamiento de cancer.
WO2011137245A3 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
WO2007044450A3 (en) Compositions and methods for the treatment of cancer